Novel derivatives of neuraminidase inhibitors and polymerase inhibitors in development are based on the same mechanism as Tamiflu, thus suffer rapid resistance development as well.
DAS181 removes the cellular receptors for the virus, the sialic acids from the cell surface. The compound is still in early clinical development
Transcription factor NF-kappa B is in early clinical development. No results have been published yet.
MEK inhibitors show strong promise as first-in-class antiviral drugs that target cellular kinases, providing all the advantages that are unmatched by current approaches.